Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher hypersensitivity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher pancreatitis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in osteonecrosis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher asparaginase‐associated toxicity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Overall survival · children and adolescents (< 18 years of age) with first‐line ALL
1 finding from 1 review
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in event‐free survival compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in hypersensitivity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in pancreatitis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in thromboembolism compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in event‐free survival compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in osteonecrosis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in asparaginase‐associated toxicity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in hypersensitivity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower pancreatitis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in thromboembolism compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in osteonecrosis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower asparaginase‐associated toxicity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Overall survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review